ARS Pharmaceuticals (SPRY) Stock Price, Quote, News & History | Benzinga

ARS Pharmaceuticals Inc (SPRY) Stock Price, Quote, News & History

SPRYNASDAQ

Trade with Public

Trade with Public

$5.65

-0.45-7.38%

At close: Aug 13, 5:00 PM EST

$5.65

-0.45-7.38%

Pre-Market: 4:11 AM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 4 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$5.65

Volume / Avg.

248.00 / 2.08M

Day Range

- - -

52 Wk Range

4.91 - 15.72

Market Cap

$561.88M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

31.1%

Days to Cover

7.78

Recent ARS Pharmaceuticals Inc News

Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.

Avi Kapoor

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.

Avi Kapoor

Can ARS Pharma's New CEO Unlock Neffy's Potential?

ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.

Vandana Singh

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc (NASDAQ: FCEL) up 17.6%, BitVentures Limited (NASDAQ: BVC) up 14.1%, and ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) up 10.3% after receiving a positive recommendation for a market authorization in Europe.

Avi Kapoor

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-196.41M

Investing Cash Flow (TTM)

48.50M

Financing Cash Flow (TTM)

104.53M

Free Cash Flow (TTM)

-196.60M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-43.38M

Analyst Trends and Forecast

1

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$514.21M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.78

PB Ratio (TTM)

44.87

Earnings Yield % (TTM)

-38.62%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.13

Company Debt

Total Debt

$96.68M

LT Debt

$96.68M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$8.16M

Debt to Equity

7.73

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$5.65

Volume / Avg.

248.00 / 2.08M

Day Range

- - -

52 Wk Range

4.91 - 15.72

Market Cap

$561.88M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

31.1%

Days to Cover

7.78

About

Sector

Health Care

Industry

Biotechnology

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intra...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy ARS Pharmaceuticals (SPRY) stock?

A

You can purchase shares of ARS Pharmaceuticals (NASDAQ:SPRY) through any online brokerage.

View our list of the best stock brokerages

Q

Who are ARS Pharmaceuticals (SPRY) competitors?

A

Other companies in ARS Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for ARS Pharmaceuticals (SPRY) stock?

A

ARS Pharmaceuticals has a consensus price target of $28.50.

Q

What is the current price for ARS Pharmaceuticals (SPRY)?

A

The stock price for ARS Pharmaceuticals (NASDAQ: SPRY) is $5.65 last updated August 17, 2026 at 4:02 AM EDT.

Q

Does ARS Pharmaceuticals (SPRY) pay a dividend?

A

There are no upcoming dividends for ARS Pharmaceuticals.

Q

When is ARS Pharmaceuticals (NASDAQ:SPRY) reporting earnings?

A

ARS Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is ARS Pharmaceuticals (SPRY) going to split?

A

There is no upcoming split for ARS Pharmaceuticals.

Q

What sector and industry does ARS Pharmaceuticals (SPRY) operate in?

A

ARS Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.